Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.16). Revenue for the quarter came in at $24.84 million versus the consensus estimate of $10.22 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.